Dianabol vs MOTS-c
Well Studied vs Well Studied
synergistic Mechanism-based · 51% Dianabol helps counteract the insulin-disrupting effects of MOTS-c. A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
Dianabol MOTS-c
Weight 300.44 Da 2,174.6 Da
Half-life ~4-6 hours ~30 minutes
Chain — 16 amino acids
Type 17-alpha-alkylated anabolic steroid (C20H28O2) Mitochondrial-derived peptide (MDP)
Key Benefits
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
MOTS-c
01 Enhanced insulin sensitivity (~30% improvement)
02 Improved glucose metabolism and tolerance
03 AMPK pathway activation
04 Mitochondrial function optimization
05 Exercise performance enhancement (12-15% improvement)
06 Potential lifespan extension (6.4% median increase in mice)
Dosing Protocols
Dianabol
20-50 mg/day / Split doses throughout the day
MOTS-c
Start 5mg daily, increase to 10-15mg based on goals / Daily for metabolic support, or 3x weekly for anti-aging
Metabolic health 5-10mg Once daily
Anti-aging protocol 15mg 3x weekly
Exercise performance 10-15mg Pre-workout
Conservative start 5mg Once daily
Side Effects
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
MOTS-c
Generally well-tolerated in animal studies with minimal side effects
Mild injection site reactions (redness, swelling)
Contraindications
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Pregnancy or breastfeeding
WADA prohibited substance (banned for athletic competition)
Limited long-term human safety data
Research Evidence
Dianabol MOTS-c
Status Well Studied Well Studied
References 5 studies 5 studies
Latest 2017 August 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.